JP2024528987A - 抗ｐｌａ２ｇ２ｄ構築物およびその使用 - Google Patents

抗ｐｌａ２ｇ２ｄ構築物およびその使用 Download PDF

Info

Publication number
JP2024528987A
JP2024528987A JP2024506669A JP2024506669A JP2024528987A JP 2024528987 A JP2024528987 A JP 2024528987A JP 2024506669 A JP2024506669 A JP 2024506669A JP 2024506669 A JP2024506669 A JP 2024506669A JP 2024528987 A JP2024528987 A JP 2024528987A
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024506669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024528987A5 (https=
Inventor
リー－フェン リー，
カン ルー，
ジェシカ ユー，
ジュリー ファン，
マデリン ウー，
アリエル ユシン チェン，
Original Assignee
エーペックスイミューン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エーペックスイミューン セラピューティクス インコーポレイテッド filed Critical エーペックスイミューン セラピューティクス インコーポレイテッド
Priority claimed from PCT/US2022/074496 external-priority patent/WO2023015225A1/en
Publication of JP2024528987A publication Critical patent/JP2024528987A/ja
Publication of JP2024528987A5 publication Critical patent/JP2024528987A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/01—Carboxylic ester hydrolases (3.1.1)
    • C12Y301/01004—Phospholipase A2 (3.1.1.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024506669A 2021-08-04 2022-08-03 抗ｐｌａ２ｇ２ｄ構築物およびその使用 Pending JP2024528987A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163229437P 2021-08-04 2021-08-04
US63/229,437 2021-08-04
PCT/US2022/074496 WO2023015225A1 (en) 2021-08-04 2022-08-03 Anti-pla2g2d constructs and uses thereof

Publications (2)

Publication Number Publication Date
JP2024528987A true JP2024528987A (ja) 2024-08-01
JP2024528987A5 JP2024528987A5 (https=) 2025-08-13

Family

ID=85128598

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024506669A Pending JP2024528987A (ja) 2021-08-04 2022-08-03 抗ｐｌａ２ｇ２ｄ構築物およびその使用

Country Status (6)

Country Link
US (1) US20240327540A1 (https=)
EP (1) EP4380690A4 (https=)
JP (1) JP2024528987A (https=)
CN (1) CN118139894A (https=)
AU (1) AU2022323177A1 (https=)
CA (1) CA3178008A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021155305A1 (en) * 2020-01-30 2021-08-05 Apeximmune Therapeutics Inc. Methods and compositions for treating cancer or viral infection with a pla2g2d antagonist

Also Published As

Publication number Publication date
CN118139894A (zh) 2024-06-04
CA3178008A1 (en) 2023-02-04
EP4380690A4 (en) 2025-02-26
AU2022323177A1 (en) 2024-03-07
US20240327540A1 (en) 2024-10-03
EP4380690A1 (en) 2024-06-12

Similar Documents

Publication Publication Date Title
JP7702961B6 (ja) 抗ｃｄ１３７コンストラクト、多重特異性抗体及びその使用
US20230365705A1 (en) Anti-cd93 constructs and uses thereof
JP7818570B2 (ja) 抗ｃｄ９３構築物およびその使用
US20230235075A1 (en) Anti-cd93 constructs and uses thereof
US20230112085A1 (en) Anti-b7-h4 constructs and uses thereof
US20220403040A1 (en) Anti-cd137 constructs, multispecific antibody and uses thereof
US20240076395A1 (en) Anti-cd137 constructs and uses thereof
US20240327540A1 (en) Anti-pla2g2d constructs and uses thereof
US20230093512A1 (en) Fusion proteins and uses thereof
US20240425588A1 (en) Anti-tigit constructs and uses thereof
WO2023015225A1 (en) Anti-pla2g2d constructs and uses thereof
EP4662236A2 (en) Anti-sirp? antibodies and uses thereof
US20260078185A1 (en) Anti-vista constructs and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250804

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250804